Daxxify® (daxibotulinumtoxinA-lanm)

Daxxify is covered only for the FDA-approved indication of cervical dystonia (spasmodic torticollis) in adults and is not covered for patients under 18 or for other indications. Coverage requires documentation of age ≥18 and medical necessity, dosing of 125–250 units intramuscularly divided among affected muscles given no more frequently than every 3 months, and approvals are valid for 12 months.

"Daxxify is indicated for the treatment of cervical dystonia in adult patients."

Sign up to see full coverage criteria, indications, and limitations.